#United States #Cincinnati #Type 1 Diabetes #Breakthrough T1D #Orlando Brown Jr.

Breakthrough T1D Gala 2026: A Night of Hope and Generosity

On May 9, 2026, the Breakthrough T1D Southern Ohio Chapter held its 42nd Annual Cincinnatian of the Year Gala, a prestigious event aimed at raising funds for type 1 diabetes (T1D) research. The gala raised over $1 million, a monumental achievement that underscores the importance of community commitment to breakthrough innovations in health care and advocacy.

The Cincinnatian of the Year award was presented to Orlando Brown, Jr., the offensive tackle for the Cincinnati Bengals and a Super Bowl Champion. His profound dedication to T1D advocacy is not just a part of his public persona; it's a deeply personal commitment stemming from his family's experiences with the disease. Brown’s younger brother lives with T1D, and the late Orlando Brown, Sr., his father, succumbed to diabetic ketoacidosis. After receiving the award, Brown emphasized the significance of using his platform to amplify awareness about T1D. He generously donated $100,000 to the organization, illustrating his commitment to the cause.

The gala featured a lively atmosphere with silent and live auctions, a heartfelt performance by the Naked Karate Girls, and the signature Fund-a-Cure segment that exclusively allocates contributions to critical research priorities. These funds are vital for advancing technology like artificial pancreas systems and beta cell replacement therapies, which hold the promise of transforming T1D management.

Petra Vester, the gala chair and long-standing volunteer with Breakthrough T1D, expressed her exhilaration over the evening’s success. Local TV personality Bob Herzog served as the master of ceremonies, guiding attendees through a night filled with hope, celebration, and community spirit. The impressive gathering illustrated the unconditional support and dedication of the T1D community.

As the event unfolded, Brown reflected on the emotional journey of families confronting T1D daily. He stated, “T1D is something that has touched my family personally, which is why partnering with Breakthrough T1D means so much to me beyond just showing up for an event.” This sentiment resonates with the purpose of the gala, which aims not only to raise funds but also to educate and provide resources for those affected by this chronic condition.

Breakthrough T1D, formerly known as JDRF, continues to be a leading global organization in research and advocacy for type 1 diabetes. Their mission revolves around enhancing the daily lives of individuals living with T1D while striving for a future where the disease can be cured. T1D, an autoimmune condition affecting nearly 9.5 million individuals worldwide, causes the pancreas to produce little or no insulin, necessitating lifelong insulin therapy. The complexity of T1D necessitates ongoing research and advocacy, and events like the Cincinnatian of the Year Gala play a critical role in keeping these initiatives alive.

For those wishing to support the cause further or to seek additional information, the organization invites donations through their website, which details ongoing efforts and research priorities. Together, these contributions enable Breakthrough T1D to continue its pivotal work in advancing the understanding and treatment of T1D, improving lives, and ultimately working towards lifesaving breakthroughs.

The success of the Cincinnatian of the Year Gala reaffirms the strength and resilience of the T1D community. As they look forward to future events and initiatives, the message remains clear: through collaboration, education, and unwavering support, a brighter future for individuals with T1D is possible.

About Breakthrough T1D

Breakthrough T1D, formerly JDRF, is dedicated to making life easier for people living with T1D. Through investing in innovative research, advocating for pivotal policies, and providing crucial education, they strive for a world where T1D is no longer a threat to lives. The organization has focused on improving daily diabetes management and enhancing research into potential cures, continuing to be a formidable ally for those affected by this condition.